Zoetis (NYSE:ZTS) & ANI Pharmaceuticals (NASDAQ:ANIP) Head to Head Contrast

Zoetis (NYSE:ZTS) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Analyst Ratings

This is a summary of current ratings and recommmendations for Zoetis and ANI Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1	12	8	0	2.33
ANI Pharmaceuticals	0	4	3	0	2.43

Zoetis currently has a consensus target price of $101.25, suggesting a potential upside of 21.91%. ANI Pharmaceuticals has a consensus target price of $100.00, suggesting a potential upside of 40.73%. Given ANI Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Zoetis.

Profitability

This table compares Zoetis and ANI Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zoetis	26.15%	85.90%	18.39%
ANI Pharmaceuticals	11.22%	28.34%	11.18%

Insider & Institutional Ownership

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 76.0% of ANI Pharmaceuticals shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Zoetis has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.

Earnings & Valuation

This table compares Zoetis and ANI Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47 billion	3.56	$2.67 billion	$5.88	14.12
ANI Pharmaceuticals	$883.37 million	1.85	$78.34 million	$5.02	14.16

Zoetis has higher revenue and earnings than ANI Pharmaceuticals. Zoetis is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Zoetis beats ANI Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

About Zoetis

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company’s rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.